Patents by Inventor Satyajit Sujit Kumar Mitra

Satyajit Sujit Kumar Mitra has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FRIZZLED-BINDING AGENTS AND USES THEREOF
    Publication number: 20170234854
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and other polypeptides, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided. Screening methods are also provided.
    Type: Application
    Filed: December 19, 2016
    Publication date: August 17, 2017
    Inventors: AUSTIN L. GURNEY, AARON KEN SATO, FUMIKO TAKADA AXELROD, TIMOTHY CHARLES HOEY, SANJEEV H. SATYAL, SATYAJIT SUJIT KUMAR MITRA
  • Wnt Antagonists and Methods of Treatment and Screening
    Publication number: 20170218041
    Abstract: The present invention relates to compositions comprising Wnt antagonists and methods of treating Wnt-associated diseases and disorders, such as cancer, inducing differentiation, and reducing the frequency of cancer stem cells, as well as novel methods of screening for such Wnt antagonists. In particular, the invention discloses soluble FZD, SFRP and Ror receptors and their use.
    Type: Application
    Filed: January 13, 2017
    Publication date: August 3, 2017
    Inventors: Sanjeev H. SATYAL, Satyajit Sujit Kumar Mitra, Austin L. Gurney
  • Wnt antagonist and methods of treatment and screening
    Patent number: 9579361
    Abstract: The present invention relates to compositions comprising Wnt antagonists and methods of treating Wnt-associated diseases and disorders, such as cancer, inducing differentiation, and reducing the frequency of cancer stem cells, as well as novel methods of screening for such Wnt antagonists. In particular, the invention discloses soluble FZD, SFRP and Ror receptors and their use.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: February 28, 2017
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra, Austin L. Gurney
  • Antibodies against human FZD5 and FZD8
    Patent number: 9573998
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: February 21, 2017
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Fumiko Takada Axelrod, Timothy Charles Hoey, Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra
  • FRIZZLED-BINDING AGENTS AND USES THEREOF
    Publication number: 20160326259
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.
    Type: Application
    Filed: January 21, 2016
    Publication date: November 10, 2016
    Inventors: Austin L. Gurney, Aaron Ken Sato, Fumiko Takada Axelrod, Timothy Chartes Hoey, Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra
  • Wnt Antagonist and Methods of Treatment and Screening
    Publication number: 20160082079
    Abstract: The present invention relates to compositions comprising Wnt antagonists and methods of treating Wnt-associated diseases and disorders, such as cancer, inducing differentiation, and reducing the frequency of cancer stem cells, as well as novel methods of screening for such Wnt antagonists. In particular, the invention discloses soluble FZD, SFRP and Ror receptors and their use.
    Type: Application
    Filed: September 1, 2015
    Publication date: March 24, 2016
    Inventors: Sanjeev H. SATYAL, Satyajit Sujit Kumar Mitra, Austin L. Gurney
  • Monoclonal antibodies against frizzled
    Patent number: 9273139
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: March 1, 2016
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Fumiko Takada Axelrod, Timothy Charles Hoey, Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra
  • Wnt antagonists and methods of treatment and screening
    Patent number: 9157904
    Abstract: The present invention relates to compositions comprising Wnt antagonists and methods of treating Wnt-associated diseases and disorders, such as cancer, inducing differentiation, and reducing the frequency of cancer stem cells, as well as novel methods of screening for such Wnt antagonists. In particular, the invention discloses soluble FZD, SFRP and Ror receptors and their use.
    Type: Grant
    Filed: January 12, 2011
    Date of Patent: October 13, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra, Austin L. Gurney
  • FRIZZLED-BINDING AGENTS AND USES THEREOF
    Publication number: 20150232554
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.
    Type: Application
    Filed: January 26, 2015
    Publication date: August 20, 2015
    Inventors: Austin L. GURNEY, Aaron Ken Sato, Fumiko Takada Axelrod, Timothy Charles Hoey, Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra
  • Polynucleotides encoding for frizzled-binding agents and uses thereof
    Patent number: 8975044
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: March 10, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Fumiko Takada Axelrod, Timothy Charles Hoey, Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra
  • Frizzled-Binding Agents And Uses Thereof
    Publication number: 20130295106
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and other polypeptides, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided. Screening methods are also provided.
    Type: Application
    Filed: March 13, 2013
    Publication date: November 7, 2013
    Inventors: Austin L. Gurney, Aaron Ken Sato, Fumiko Takada Axelrod, Timothy Charles Hoey, Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra
  • FRIZZLED-BINDING AGENTS AND USES THEREOF
    Publication number: 20130295105
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.
    Type: Application
    Filed: March 13, 2013
    Publication date: November 7, 2013
    Inventors: Austin L. GURNEY, Aaron Ken Sato, Fumiko Takada Axelrod, Timothy Charles Hoey, Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra
  • FRIZZLED-BINDING AGENTS AND USES THEREOF
    Publication number: 20130252326
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.
    Type: Application
    Filed: March 13, 2013
    Publication date: September 26, 2013
    Applicant: ONCOMED PHARMACEUTICALS, INC.
    Inventors: AUSTIN L. GURNEY, AARON KEN SATO, FUMIKO TAKADA AXELROD, TIMOTHY CHARLES HOEY, SANJEEV H. SATYAL, SATYAJIT SUJIT KUMAR MITRA
  • Methods of use for an antibody against human frizzled receptors 1, 2. 5, 7 or 8
    Patent number: 8507442
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.
    Type: Grant
    Filed: June 20, 2011
    Date of Patent: August 13, 2013
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Fumiko Takada Axelrod, Timothy Charles Hoey, Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra
  • FRIZZLED-BINDING AGENTS AND USES THEREOF
    Publication number: 20110318341
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.
    Type: Application
    Filed: June 20, 2011
    Publication date: December 29, 2011
    Inventors: Austin L. Gurney, Aaron Ken Sato, Fumiko Takada Axelrod, Timothy Charles Hoey, Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra
  • Wnt Antagonists and Methods of Treatment and Screening
    Publication number: 20110305695
    Abstract: The present invention relates to compositions comprising Wnt antagonists and methods of treating Wnt-associated diseases and disorders, such as cancer, inducing differentiation, and reducing the frequency of cancer stem cells, as well as novel methods of screening for such Wnt antagonists. In particular, the invention discloses soluble FZD, SFRP and Ror receptors and their use.
    Type: Application
    Filed: January 12, 2011
    Publication date: December 15, 2011
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Sanjeev H. SATYAL, Satyajit Sujit Kumar Mitra, Austin L. Gurney
  • Frizzled-binding agents and uses thereof
    Patent number: 7982013
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.
    Type: Grant
    Filed: September 28, 2009
    Date of Patent: July 19, 2011
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Aaron Ken Sato, Fumiko Takada Axelrod, Timothy Charles Hoey, Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra
  • Frizzled-Binding Agents and Uses Thereof
    Publication number: 20100104574
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.
    Type: Application
    Filed: September 28, 2009
    Publication date: April 29, 2010
    Inventors: Austin L. Gurney, Aaron Ken Sato, Fumiko Takada Axelrod, Timothy Charles Hoey, Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra